Abstracts - faqs.org

Abstracts

Business, international

Search abstracts:
Abstracts » Business, international

OxyContin maker, insurer settle legal-bill dispute

Article Abstract:

Purdue Pharma L.P. of the United States has a confidential settlement with its insurer Steadfast Insurance Co. also of the United States. Under the settlement the insurance company will pay only $200 million in defense costs instead of $400 million. The costs were due to consumer claims that the OxyContin drug was addictive.

Author: Raghaven, Anita, Teariero, Heather Won
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2006
Fire, marine, and casualty insurance, Property and casualty insurance industry, Purdue Pharma L.P., Steadfast Insurance Co.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Glaxo and Mylan settle patent dispute over Paxil

Article Abstract:

UK pharmaceutical firm GlaxoSmithKline PLC and US generic drugs manufacturer Mylan Inc. have settled a case over the patent for Paxil CR, an antidepressant drug. Mylan will obtain the right to market paroxetine hydrochloride, a generic version of the Glaxo drug, by Oct. 1, 2008. Both companies have dropped all litigation.

Author: Berton, Elena
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2007
Other Justice, Public Order, and Safety Activities, Patents & copyrights, Patent Law, Intellectual property, Paroxetine, Mylan Inc., Paxil CR (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Shareholders sue Glaxo over Avandia disclosure

Article Abstract:

Shareholders of British pharmaceutical company GlaxoSmithKline PLC have sued the firm in a New York federal court, claiming it misled them regarding the safety of Avandia, a diabetes drug. The suit states that Glaxo did not inform investors that an analysis had linked the drug to an elevated risk for heart attacks.

Author: Whalen, Jeanne
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2007
Financial management, Stockholder Suits, Complications and side effects, Investor relations, Avandia (Medication), Stockholders' derivative actions, Shareholder lawsuits

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Company legal issue, Cases, Pharmaceutical industry, United Kingdom, GlaxoSmithKline PLC
Similar abstracts:
  • Abstracts: Consumer surplus vs. welfare standard in a political economy model of merger control. Leniency programs and cartel prosecution
  • Abstracts: Corus specializes in putting together steel product and service packages. Robin Snell/Water Activity Centre
  • Abstracts: Fortis makes bid of $1.27 billion for Turkish bank. Barclays says it will hit profit goal. ABN Amro's earnings rise by 12 percent
  • Abstracts: EU is planning measures to protect biofuels industry. EU pacts with Kazakhstan aim to ease reliance on Russia for gas
  • Abstracts: Ferrovial wins battle for BAA. FCC cement unit to buy stake in Spain's Uniland
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.